<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370018</url>
  </required_header>
  <id_info>
    <org_study_id>R06-005</org_study_id>
    <nct_id>NCT01370018</nct_id>
  </id_info>
  <brief_title>Therapy to Elevate CD4 Counts in HIV-1 Disease</brief_title>
  <official_title>Zemaira (Alpha-1-Proteinase Inhibitor) Therapy in HIV-1 Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Human Genetics and Biochemistry</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute for Human Genetics and Biochemistry</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      For more than 20 years, alpha-1-proteinase inhibitor therapy has been the standard treatment&#xD;
      for patients who have inherited alpha-1-proteinase inhibitor deficiency. Adult patients with&#xD;
      this condition eventually develop emphysema. Most HIV-1 patients who have low viral load also&#xD;
      have alpha-1-proteinase inhibitor deficiency. The number of CD4 cells in blood increases when&#xD;
      alpha-1-proteinase inhibitor increases. Patients will be asked to participate in a pilot&#xD;
      study to see whether the use of Zemaira® (alpha-1-proteinase inhibitor) can increase blood&#xD;
      levels of alpha-1-proteinase inhibitor and consequently increase CD4 counts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-1 patients will be asked to participate in a pilot study to see whether the use of&#xD;
      Zemaira increases blood levels of alpha-1-proteinase inhibitor and consequently increase CD4&#xD;
      counts.&#xD;
&#xD;
      HIV-1 patients will receive weekly treatment with Zemaira for 8 weeks by intravenous&#xD;
      infusion. Blood will be collected immediately prior to each infusion. Blood will be collected&#xD;
      at each visit. Exploratory assessments and not pre-specified outcome measurements will&#xD;
      include complete blood count, lymphocyte phenotype, HIV-1 viral load, lipid levels, blood&#xD;
      chemistry, and markers of inflammation from patient medical records. Exploratory and not&#xD;
      pre-specified outcome measures will include extended lymphocyte phenotype and lymphocyte&#xD;
      function using residual blood collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD4/CD8 Ratio</measure>
    <time_frame>9 weeks after initiation of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>HIV Disease</condition>
  <arm_group>
    <arm_group_label>alpha-1 proteinase inhibitor in HIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-1 infected individuals treated with Alpha-1 proteinase inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alpha-1-Proteinase Inhibitor</intervention_name>
    <description>Alpha-1-Proteinase Inhibitor was delivered I.V. A patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of alpha-1-Proteinase Inhibitor. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of alpha-1-Proteinase Inhibitor for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers, and alpha-1-Proteinase Inhibitor.</description>
    <arm_group_label>alpha-1 proteinase inhibitor in HIV</arm_group_label>
    <other_name>Zemaira</other_name>
    <other_name>Prolastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HIV-1 patients must have confirmed HIV-1 disease, diagnosed using the standard&#xD;
             criteria and be on antiretroviral therapy. Patients with inherited alpha-1 proteinase&#xD;
             inhibitor deficiency (PIzz) must not have previously received alpha-1 proteinase&#xD;
             inhibitor therapy. Uninfected volunteers will be age and gender matched.&#xD;
&#xD;
          2. HIV-1 patients must have measurable disease, defined as HIV-1 infected patients on&#xD;
             antiretroviral therapy with undetectable HIV RNA (&lt;500 HIV-1 RNA copies/ml) and CD4&#xD;
             counts more than 200 and less than 400 cells/uL.&#xD;
&#xD;
          3. Age at least 18 years and under 65 years.&#xD;
&#xD;
          4. HIV-1 patients must have active alpha-1 proteinase inhibitor below 11uM (normal is&#xD;
             18-53 uM).&#xD;
&#xD;
          5. HIV-1 patients must have one year history (prior to the study) with CD4 counts greater&#xD;
             than 200 and less than 400 cells/uL.&#xD;
&#xD;
          6. Volunteers must have no evidence of malignancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recent illness that will prevent the patient from participating in required study&#xD;
             activities.&#xD;
&#xD;
          2. Patients receiving other investigational agents.&#xD;
&#xD;
          3. Patients with known malignancies.&#xD;
&#xD;
          4. Patients with more than 500 HIV RNA copies/mL.&#xD;
&#xD;
          5. Patients with more than 400 CD4 cells/uL.&#xD;
&#xD;
          6. Uncontrolled illness including, but not limited to, ongoing or active infection,&#xD;
             myeloid dysplastic syndrome, anemia, bone marrow failure, DiGeorge Syndrome, thymic&#xD;
             disorders, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female subjects were not included in this pilot study to avoid pregnancy-related issues.</gender_description>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia L Bristow, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Cortes, MD</last_name>
    <role>Study Director</role>
    <affiliation>Beth Israel Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cabrini Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bristow, C.L., Cortes, J., Mukhtarzad R., Trucy, M., Franklin, A., Romberg, V., Winston, R. 2010. α1Antitrypsin therapy increases CD4+ lymphocytes to normal values in HIV-1 patients. In Soluble Factors Mediating Innate Immune Responses to HIV Infection, (ed. M. Alfano). Bentham Science Publishers, http://www.alpha1biologics.com/BristowChapter.pdf</citation>
  </results_reference>
  <results_reference>
    <citation>Bristow CL, Modarresi R, Babayeva MA, LaBrunda M, Mukhtarzad R, Trucy M, Franklin A, Reeves RE, Long A, Mullen MP, Cortes J, Winston R. A feedback regulatory pathway between LDL and alpha-1 proteinase inhibitor in chronic inflammation and infection. Discov Med. 2013 Nov;16(89):201-18.</citation>
    <PMID>24229737</PMID>
  </results_reference>
  <results_reference>
    <citation>Bristow CL, Ferrando-Martinez S, Ruiz-Mateos E, Leal M, Winston R. Development of Immature CD4(+)CD8(+)T Cells Into Mature CD4(+) T Cells Requires Alpha-1 Antitrypsin as Observed by Treatment in HIV-1 Infected and Uninfected Controls. Front Cell Dev Biol. 2019 Nov 21;7:278. doi: 10.3389/fcell.2019.00278. eCollection 2019.</citation>
    <PMID>31824943</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 6, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <results_first_submitted>January 6, 2014</results_first_submitted>
  <results_first_submitted_qc>August 31, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 28, 2021</results_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Human Genetics and Biochemistry</investigator_affiliation>
    <investigator_full_name>Cynthia L Bristow, PhD</investigator_full_name>
    <investigator_title>Assistant Professor, Mount Sinai School of Medicine</investigator_title>
  </responsible_party>
  <keyword>CD4 counts</keyword>
  <keyword>cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alpha-1-Proteinase Inhibitor/HIV</title>
          <description>This pilot study was performed to examine the efficacy of alpha-1 proteinase inhibitor augmentation in HIV-1 infected patients undergoing research treatment to elevate alpha-1-proteinase inhibitor and thereby, CD4 helper immune cells.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet criteria for analysis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>HIV patients were receiving antiretroviral medication with adequate suppression of virus. No patients had previously received alpha-1 proteinase inhibitor treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Alpha-1-Proteinase Inhibitor in HIV</title>
          <description>This pilot study was performed to examine the efficacy of alpha-1 proteinase inhibitor augmentation in 4 HIV-1 infected patients undergoing research treatment to elevate alpha-1-proteinase inhibitor and thereby, CD4 helper immune cells.Study subjects were evaluated at Baseline and weekly for at least 8 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 counts</title>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="294" spread="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD8</title>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="829" spread="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4/CD8 Ratio</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.40" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>active alpha-1 proteinase inhibitor</title>
          <units>μM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CD4/CD8 Ratio</title>
        <time_frame>9 weeks after initiation of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alpha-1-Proteinase Inhibitor in HIV</title>
            <description>This pilot study was performed to show that Zemaira® treatment can be used in HIV-1 patients to elevate alpha-1-Proteinase Inhibitor and has the added benefit of elevating CD4 cells.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4/CD8 Ratio</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 weeks to 1 year post therapy</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Alpha-1-Proteinase Inhibitor</title>
          <description>This pilot study was performed to show that Zemaira® treatment can be used in HIV-1 patients to elevate alpha-1-Proteinase Inhibitor and has the added benefit of elevating CD4 cells.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One HIV infected patient enrolled, but entered the study with elevated inflammatory markers which were were not within the eligibility criteria.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Cynthia L. Bristow, MS, PhD</name_or_title>
      <organization>Institute for Human Genetics and Biochemistry</organization>
      <phone>6314446238</phone>
      <email>cynthia.bristow@alpha1biologics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

